market cap $220M small cap...board has ex-pepsi CEO (was also ex-apple CEO), Kerug CEO, COO from Starbucks SVP, Bio side founder is Nobel prize winner, Biogen CMO, all others from Harvard. Very strong consumer and bio people. Going to make money on BOTH consumer side and biotech side. Just starting prelaunch of product with 0 competition.
Here is the best part....over $10 million INSIDER BUYS from open market in March and May ! Almost daily insider buys by CEO. Stock trading still under IPO price from last year.
got your attention didn't I ?? Go check it out....think story is big and story/management is there it back up the story.
do dilution at much lower PPS than market ? OVAS could have easily done it at current PPS, and made much more $ for themselves at same share count. Since this is being sold internally, and not being sold to some other party, why sell at $7 instead of $9 ??
very strong bio and consumer side management...part of longwood funds....ex CEO pepsi/apple, ex CEO Keurig on board, COO is SVP Sarbucks, all Harvard people in advisory board, founder is nobel prize winner. Major catalyst coming June, stock market cap $220M.
MAJOR insider buying in May.
what gives. Are they going out of biz.
they got strong talent like ex-pepsi, ex-apple, ex-keurig, starbucks etc. to help get the consumer side launched. Agreed with the name, but go check out facebook and twitter. Very positive reviews coming in. Word will spread, 3 investor conferences this month. Olympics coming up. Founder just said people are removing other benefits other than cramps. The neomuscular benefits seems to be expanding.
Right now 3 cities, July I assume more stores in other cities will start carrying imo.
why would you sell based on the 'name'....its the product that sells. I'm sure 'facebook' seemed a dumb name in the beginning.
no research clinical company is presenting there...it is all academic only...universities. I don't think AVXL will present there..in case people are hoping. Next presentation is CTAD in December...which is where they presented last year. That is more research clinical based, and more appropriate for AXON, AVXL etc.
only thing that will turn company around is overture...all rest - ovaprime, argment...I agree..marginally better, niche. Wait for overture, but could be 1 year out
The day they announce plan to launch ovature, buy the stock....all rest is not going to set stock moving. Replacing hormone treatment is the big story with this stock. Even CEO says buy the company for ovature, not for rest. I assume all the insider buying at 7s, 9s, etc...are all getting ready for ovature...but that is still 1 year out minimum.
Even Japan for augment is 1 year out.
so far no news...which is strange given wk12 ended in January. Why do a late breaking when wk12 ended so long ago ? Don't know if they will present, but without AAIC something is very strange going on.
I understand they said data will be presented in scientific conferences...so last chance is AAIC. I understand the embargo thing. So again, last chance is AAIC. So far no news of AAIC attendance, is not good....they should have submitted their abstract by now to AAIC. Are they waiting for end of June ? Why
only McFarlane. Will rehash same old info